Poll: What do you Think of "Female Viagra"?
A Phase II trial is underway for Tefina, a testosterone-based treatment for female sexual dysfunction.
A Phase II trial is underway for Tefina, a testosterone-based treatment for female sexual dysfunction. Nicknamed “the female Viagra,” the drug is administered via a nasal spray two hours before sexual activity, and is believed to increase desire and stimulate blood flow to the sexual organs, making it appropriate for both women with low desire as well as women with difficulty climaxing.
One fertility specialist, Ric Gordon, said he believed that the drug was “exploiting” female sexuality, because it overlooked the reasons behind a low sexual drive. He maintained that “men use sex to de-stress and women need to be de-stressed to have sex,” and so by bringing this drug to market, more complicated emotional issues will be ignored
Online Poll
|
Online Survey
Please add your thoughts in the Comments section below.
SART data indicates rise in IVF use in 2022
April 24th 2024Dive into the latest statistics from the Society for Assisted Reproductive Technology, revealing a 6% increase in in vitro fertilization cycles and a surge in egg freezing, amidst a landscape of rising fertility service demand and evolving clinical practices.
Read More
In this episode of Pap Talk, Gloria Bachmann, MD, MSc, breaks down what it means to be a health care provider for incarcerated individuals, and explores the specific challenges women and their providers face during and after incarceration. Joined by sexual health expert Michael Krychman, MD, Bachmann also discusses trauma-informed care and how providers can get informed.
Listen
Excessive gonadotropins in IVF: Effects on mosaicism and live birth
April 12th 2024A recent study revealed a correlation between high doses and prolonged duration of exogenous gonadotropin use during in vitro fertilization and increased embryonic mosaicism alongside diminished live birth rates, prompting reconsideration of dosage and duration protocols.
Read More
